Market
Synopsis of Global Lung Cancer Market:
Market
Scenario:
The Lung
cancer Market is growing mainly due to the changing lifestyle, and
environmental pollution. According to a recent study report published by the
Market Research Future, The lung cancer market is booming and expected to gain
prominence over the forecast period. The market is forecasted to demonstrate a
spectacular growth by 2023, surpassing its previous growth records in terms of
value with a striking CAGR of 13.5% during the anticipated period (2017 –
2023).
Lung
cancer is a malignant lung tumor characterized by uncontrolled cell growth in
lung tissue with symptoms such as coughing, weight loss, and fatigue and chest
pain. The two types of lung cancers are small-cell lung cancer (SCLC) and
non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of
the total lung cancers. The cure rates for the two types of lung cancers
exchange their positions with the SCLC being the most malignant. The cure rates
also depend on the stage of cancer detection with rates varying by 55% for
first stage to just 1% for stage four.
Almost 85%
of cases of lung cancer are due to long-term tobacco smoking. Cigarette smoke
contains at least 73 known carcinogens. Other factors causing lung cancer are
genetic factors and exposure to triggers and carcinogens such as radon gas,
asbestos, radioactive materials, second-hand smoke, or air pollution. It has
also been demonstrated that passive smokers have a 20–30% increase in risk.
The
treatments for lung cancer include surgery, chemotherapy, and radiotherapy with
NSCLC responding better to surgery and SCLC usually responding better to
chemotherapy and radiotherapy. Notably, smoking is the primary driver for the
rising cases of lung cancer. According to World Health Organization (WHO)
tobacco kills more than 7 million people each year of which more than 6 million
deaths are the result of direct tobacco use. Lung cancer is the leader with a
whopping 37% of deaths. Of more concern is the rising rates of lung cancer due
to passive smoking.
Other
push factors such as, environmental pollution, rising cases of infections,
growing rates of early detection and awareness, rising rates of fast growing
lung cancer, and reimbursements and growing health insurance are also fuelling
the growth of the market.
Despite
these drivers, poor efficacy, cure rates and side effects of present treatment,
high failure rates of lung transplant surgeries, high malignant nature and
faster growth of lung cancer, poor life expectancy and quality of life of
patients undergoing lung cancer treatment, and scarcity of lung organ and long
waiting lines are expected to decline the market growth. According to American
Society of Clinical Oncology (ASCO) the 5-year survival rate for stage I NSCLC
is about 47% which falls drastically to 10% for stage III. The 5-year survival
rate for stage IV NSCLC is just around 1%.
Key Players for Global Lung
Cancer Market:
·
F. Hoffmann-La Roche AG
·
Novartis
·
PFIZER INC
·
Merck & Co., Inc.
·
BRISTOL-MYERS SQUIBB
·
ELI Lilly and Company
·
Sanofi
Segments:
Global
Lung Cancer Market has been segmented on the basis of types which comprises of
SCLC and NSCLC. On the basis of treatments it is segmented into Surgery,
Chemotherapy, Radiotherapy, Photodynamic therapy (PDT) and Laser therapy. On
the basis of end users, it includes Hospitals & Clinics, Cancer Research Centers
and Laboratories.
Regional
Analysis:
The
global market for Lung Cancer is growing steadily. The global lung cancer
market on the basis of region comprises of North America, Europe, Asia Pacific
and Middle East & Africa. The global market for Lung Cancer is growing with
the CAGR of 13.5% during the forecast period from 2017-2023. NSCLC is the most
common type of lung cancer globally. The global Lung Cancer market reached USD
36929.8 million in 2023 from 15219.7 million in 2016. Europe region captured
the second largest market globally and is expected to reach USD 8,536.3 million
by 2023 due to the growing demand and need for lung cancer drugs, and the
growing prevalence of lung cancer.
Browse Complete 108 Pages Premium Research Report Enabled with
121 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/lung-cancer-market-1185
Detailed Table Of Contents
1 Report Prologue
2 Introduction
2.1
Research Objective
2.2
Assumptions & Limitations
2.2.1
Assumptions
2.2.2
Limitations
2.3
Market Structure
3 Research Methodology
3.1
Primary Research
3.2
Secondary Research
4 Porters Five Forces
4.1
Introduction
4.2
Bargaining Power Of Buyer
4.3
Bargaining Power Of Suppliers
4.3.1
Threat From Substitute
4.3.2
Threat From A New Entrant
4.3.3
Intensity Of Competitive Rivalry
5 Market Dynamics
5.1
Drivers
5.1.1
Smoking
5.1.2
Environmental Pollution
5.1.3
Rising Cases Of Infections
5.1.4 Growing
Rates Of Early Detection And Awareness
5.1.5
Rising Rates Of Fast Growing Lung Cancer
5.1.6
Reimbursements And Growing Health Insurance
...Continued
About US:
Market Research Future (MRFR), enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment